主页 > 医学前沿 >
【drug-news】阿利吉仑(新型肾素抑制剂 )
Aliskiren is the first orally active inhibitor of renin to be approved for clinical use as an antihypertensive agent. The development program has established that at the licensed doses of 150 mg and 300 mg, there are dose-related falls in blood pressure comparable to those seen with other major classes of antihypertensive drugs and that these falls are associated with a placebo level of side effects. Aliskiren was found to be effective either as monotherapy or in combination with drugs from the other major classes. As expected, there was a greater benefit from adding aliskiren to natriuretic drugs than to other blockers of the renin system. However, there was also some consistent benefit from dual renin blockade. Aliskiren is likely to be of most value in patients uncontrolled by, or intolerant of, other classes. Rational understanding of the renin system will maximize its value, for instance, by encouraging greater use of natriuretic agents in patients with resistant hypertension to render their hypertension renin dependent. Whether there are cardiovascular benefits other than blood pressure control in blocking the renin system remains to be demonstrated. It is hoped that long-term outcome studies with aliskiren will finally allow this question to be answered.
Key Words: aliskiren • renin • renin inhibitor
Circulation,8月12日
Aliskiren.pdf (655.87k) 肾素抑制剂是很好的药物。我记得在本科学药理时，讲这个课的时候，因为肾素-血管紧张素系统有多个靶点可以进行设计药物，而对于肾素的抑制则是这个系统的最后药物。当时金满文教授讲这个RAAS时，他都会讲到这个系统最新的研发情况，都是最新的前沿，他也一直关注肾素抑制药，记得好像是去年四月吧，这个肾素抑制药终于被FDA批准上市，算是心血管系统药物中非常重大的事件。
原先我一直是准备搞心血管的，虽然后来偶然的做了神经药理，今后也是搞神经了，但是心血管我一直会关注的。呵呵~ [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-04-20 05:14
医学,生命科学网